



Qualification Statistical Report

Method: VSDVAC 58 Version 0.00, An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum

PPD Project Code: ROQP2

Qualification of An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum

Version: 1.0

Conducted for PPD Laboratory

**by PPD[®] Laboratories
2244 Dabney Road
Richmond, Virginia 23230
(804) 359-1900**

Original Document Date: 19 June 2020

Revision Date: NA

Confidentiality Statement

The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you which is indicated as privileged or confidential.

PPD SIGNATURES

Prepared By:



Tina Green
Director, Biostatistics
I am the author of this document
19 Jun 2020 19:13:09 -04:00

DocuSign

Tina Green
Director, Biostatistics
PPD Laboratories

Date

Second-Statistician Reviewer:



Victoria A. Piscella
Senior Biostatistician II
I reviewed this document
19 Jun 2020 16:50:50 -04:00

DocuSign

Victoria Piscella
Senior Biostatistician II, Biostatistics
PPD Laboratories

Date

Scientific Contribution by:



Jack Hester
Associate Group Leader
I approve this document
19 Jun 2020 16:57:02 -04:00

DocuSign

Jack Hester
Associate Group Leader
PPD Laboratories

Date

PPD Signatures

Scientific Reviewer:




Adrienne Howlett
Sr. Group Leader
I reviewed this document
19 Jun 2020 17:09:22 -04:00

DocuSign

Adrienne Howlett
Senior Group Leader
PPD Laboratories

Date

Scientific Approver:



Marie Bonhomme
Associate Director
I approve this document
19 Jun 2020 16:57:35 -04:00

DocuSign

Marie Bonhomme, Ph.D.
Associate Director
PPD Laboratories

Date

Quality Assurance Reviewer:

(b) (6)

(b) (6)

I reviewed this document
19 Jun 2020 18:03:09 -04:00

DocuSign

(b) (6)

Date

PPD Global Quality and Compliance

cc List: Lisa Strelow

EXPERIMENT BACKGROUND AND PURPOSE

A proprietary serological method, *An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum* was developed and was qualified by PPD[®] Laboratories, in Richmond, Virginia, USA. The qualification of this new method was conducted under PPD Project Code “ROQP2”. The new method, VSDVAC 58^[1], will be finalized to version 1.00 after qualification.

A qualification plan^[2] was developed and approved to qualify the SARS-CoV-2 ELISA. The purpose of the qualification experiment was to establish the (b) (4) (b) (4) of the SARS CoV-2 spike proteins. The purpose of this report is to document the operating characteristics of the assay. The SARS-CoV-2 operating characteristics are summarized below and in [Table 1](#).

Qualification Results Summary

Assay Characteristic	Qualification Results
	(b) (4) (4)
Assay Validity Criteria	<i>The assay plate is considered invalid if</i> (b) (4) (4)
	<i>The assay run is considered invalid if</i> (6) (b) (4) of the plates fail (using the validity criteria described above).
Standard Curve Modeling	(b) (4) (4)

Assay

Characteristic • Qualification Results

(b) (4)

Scientific Contribution

The SARS-CoV-2 ELISA is considered qualified. The (b) (4) (b) (4) (preliminary data) were deemed acceptable upon completion of the statistical analysis.

(b) (4)

Conclusion

The SARS-CoV-2 ELISA is considered qualified with regard to (b) (4) (b) (4) The assay is also considered acceptably (b) (4) however, (b) (4) will be further confirmed in an Addendum to the Qualification Report.

The SARS-CoV2 spike ELISA is considered acceptable for use in the assessment of phase II clinical samples. (b) (4) (b) (4) (b) (4)

Table 1
Parameter Summary Table
All limits are inclusive unless otherwise noted.

Assay Characteristic	SARS-CoV-2
(b)	(4)

TABLE OF CONTENTS

PPD SIGNATURES..... 2

EXPERIMENT BACKGROUND AND PURPOSE..... 4

 QUALIFICATION RESULTS SUMMARY..... 4

 SCIENTIFIC CONTRIBUTION 6

 CONCLUSION..... 6

Table 1 7

TABLE OF CONTENTS 8

ACRONYMS AND DEFINITIONS..... 10

SCOPE 11

STUDY OBJECTIVES & DESIGN..... 11

 STUDY OBJECTIVES 11

 PLATE LAYOUT 11

Figure 1..... 12

EXPERIMENTAL DESIGN..... 12

 (b) (4) .. 13

Table 2 14

Figure 2..... 14

 (b) (4) ... 15

Table 3 15

Figure 3..... 16

 (b) (4) 18

Figure 3.1..... 18

 (b) (4) 19

Figure 4..... 19

Table 4 20

Table 5 21

STATISTICAL METHODS AND RESULTS 22

 (b) (4) 22

Figure 5..... 23

Table 6 23

Table 7 24

 (b) (4) 24

Table 8 25

 (b) (4) 26

Table 9 28

Table 10 28

 (b) (4) 29

Table 11 29

Figure 6..... 30

Table 12 31
(b) (4) 32
Figure 7 33
Table 13 34
(b) (4) 34
Table 14 35
Figure 8 36
(b) (4) 37
Table 15 38
(b) (4) 39
Figure 9 40
Table 16 40
(b) (4) 41
Figure 10 42
Table 17 42
(b) (4) 43
Figure 10.1 44
Table 17.1 44
(b) (4) 45
Table 18 46
REFERENCES 46
REVISION HISTORY 46
Attachment I 47
Attachment II 48
Attachment III 49
Attachment IV 50
Attachment V 51
Attachment VI 54
Attachment VII 55
Attachment VIII 57
Attachment VIII.1 58
Attachment IX 59
Attachment IX.1 60
Attachment IX.2 61

ACRONYMS AND DEFINITIONS


Acronyms	Definitions
Abs	Absolute
Ab[C]	Antibody Concentration
(b) (4)	
Conc.	Antibody Concentration Measured in µg/mL
Diff	Difference
(b) (4)	
ELISA	Enzyme-Linked Immunosorbent Assay
Exp.	Expected
(b) (4)	
GM	Geometric Mean
GMC	Geometric Mean Antibody Concentration
GMedC	Geometric Median Concentration
IgG	Immunoglobulin-G
(b) (4)	
mL	Milliliter(s)
NA	Not Applicable
NE	Not Estimable
NIH	National Institute of Health
NT	Not Tested
Obs.	Observed
OD	Optical Density
PF	Plate Failure
QA	Quality Assurance
QC	Quality Control
QCS	Quality Control Serum or Samples
(b) (4)	
Ratio	Maximum(OD)/Minimum(OD)
Rep	Replicate
(b) (4)	
Run	A group of analytical samples consisting of standard curve, QCS, blank and test samples processed across a minimum of one plate.
SARS	Sudden Acute Respiratory Syndrome
SAS	Statistical Analysis Software
(b) (4)	
SOP	Standard Operating Procedure
SPAR	See Periodic Analysis Results (trending)
SR	Spike and Recovery
(b) (4)	
VSD	Vaccine Sciences Department
Work Order	Unique run identifier assigned by LIMS
(b) (4)	

SCOPE

The scope of this qualification is limited to documenting the operating characteristics of the method for the detection of IgG specific to SARS-CoV-2 Spike protein in human serum. All sample test results will be used for assay qualification purposes only and will not be included in the analysis of any clinical trial or epidemiology study. The assay and data are not designed for medical or diagnostic purposes and will be used to support Phase I/II studies only.

STUDY OBJECTIVES & DESIGN**Study Objectives**


For the assay under evaluation, the objectives of the qualification experiments were to:



(b) (4)

Plate Layout


The following sample types were analyzed in each qualification run:




(b) (4)

An example of the typical plate layout is provided in [Figure 1](#).

Figure 1
Generic Plate Layout




EXPERIMENTAL DESIGN




(b) (4)

Table 2
(b) (4)



The table content is redacted with a large grey block. The redaction is labeled with '(b) (4)' in large black font.

Figure 2



(b) (4)

Table 3


(b) (4)

(b) (4)

Figure 3

(b) (4)

Figure 3



(b) (4)

Figure 3.1

(b) (4)

(b) (4)

Figure 4


(b) (4)

Table 4
Experimental Design

(b) (4)

Table 5
Sample Description for Samples Used within Each of the Experiments

Experiment	Sample	Serum ID	Experiment	Sample	Serum ID
------------	--------	----------	------------	--------	----------



STATISTICAL METHODS AND RESULTS

(b) (4)

Figure 5


(b) (4)

Table 7

(b) (4)

(b) (4)

Table 8



(b) (4)

(b) (4)

Quality Control Samples (QCS)

(b) (4)

Run Suitability

Using the criteria stated above, the assay run is considered invalid if (b) (4) % of the plates fail.

Table 9

(b) (4)

Table 10

(b) (4)

(b) (4)

Table 11

(b) (4)

Figure 6

(b) (4)

(b) (4)

Table 12

(b) (4)

(b) (4)

Figure 7

(b) (4)

Table 13

(b) (4)

Table 14

(b) (4)

Figure 8

(b) (4)

(b) (4)

Table 15

(b) (4)

(b) (4)

Figure 9

(b) (4)

Table 16

(b) (4)

(b) (4)

Figure 10

(b) (4)

Table 17

(b) (4)

(b) (4)

Figure 10.1

(b) (4)

Table 17.1

(b) (4)

(b) (4)

Table 18

(b) (4)

References

1. Draft Method: VSDVAC58: *An ELISA method for the detection of IgG specific to SARS-CoV-2 Spike protein in human serum*, V0.00.
2. (b) (4)
3. PPD Method Qualification Plan: *An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum*. ROQP2, 04Jun2020
4. PPD Method Qualification Plan Amendment 1: *Qualification of An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum*. ROQP2, 05Jun2020
5. PPD Method Qualification Plan Amendment 2: *Qualification of An ELISA Method for the Detection of IgG Specific to SARS-CoV-2 Spike Protein in Human Serum*. ROQP2, 09Jun2020.
6. Event QEI #780. ROQP2: VSDVAC 58_QP (b) (4) Repeat, Date opened 11Jun2020.
7. Event QEI #694: ROQP2: Errors found in the VSDVAC 58 Qualification Plan, Date opened 08Jun2020.

Revision History

Version	Date	Author	Reason for Revision
1.0	19-June-2020	Tina Green	Original Version

Attachment I

(b) (4)

Attachment II

(b) (4)

Attachment III

(b) (4)

Attachment IV

(b) (4)

Attachment V

(b) (4)

Attachment V

(b) (4)

Attachment V

(b) (4)

Attachment VI

(b) (4)

Attachment VII

(b) (4)

Attachment VII

(b) (4)

Attachment VIII

(b) (4)

Attachment VIII.1

(b) (4)

Attachment IX

(b) (4)

Attachment IX.1

(b) (4)

Attachment IX.2

(b) (4)